Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Featured Journal Content

 

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

News: EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen
Last updated: 16/02/2021
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by Janssen-Cilag International N.V.
EMA’s human medicines committee (CHMP) will assess the vaccine, known as COVID-19 Vaccine Janssen, under an accelerated timetable. The Committee could issue an opinion by the middle of March 2021, provided the company’s data on the vaccine’s efficacy, safety and quality are sufficiently comprehensive and robust.
Such a short time for evaluation is only possible because EMA has already reviewed some data during a rolling review